How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

J Clin Oncol. 2024 May 20;42(15):1734-1737. doi: 10.1200/JCO.23.01241. Epub 2024 Mar 14.

RPT-TEC group:
Tom Bäck, Manuel Bardies, Alessandro Bartolini, Sören Bentzen, Peter Bernhardt, Ingrid Bloise, Lisa Bodei, Wesley Bolch, Patrik Brodin, Julia Brosch-Lenz, Jacek Capala, Carlo Chiesa, Patricia E Cole, Marta Cremonesi, Emmanuel Deshayes, Yuni Dewaraja, Roberto Formento-Cavaier, Gerhard Glatting, Harwig Hennekes, Jacob Hesterman, Rob Hobbs, Vicki Jardine, Jessica Jensen, Adam Kesner, Ana P Kiess, Mark W Konijnenberg, Clemens Kratochwil, Phillip H Kuo, Roberto Maass-Moreno, Michael Morris, Quyen Nguyen, Joseph O'Donoghue, Stig Palm, Neeta Pandit-Taskar, Laurens Raes, Hendrik Rathke, Babak Saboury, Nicola Salem, Lore Santoro, Oliver Sartor, Mike Sathekge, George Sgouros, Eileen Sneeden, Lidia Strigari, Scott Tagawa, Carlos Uribe, Amanda Walker, Wolfgang Weber, Fred Wilson, Tahir Yusufaly, Sabine Zitzmann-Kolbe

¹ Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
² Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Functional Imaging, BC Cancer, Vancouver, BC, Canada.
⁴ Department of Radiology, University of British Columbia, Vancouver, BC, Canada.
⁵ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁶ Ratio Therapeutics, Inc, Boston, MA.
⁷ Department of Radiology, Johns Hopkins Medical Institutes, Baltimore, MD.

No abstract available

MeSH terms